Aprea Therapeutics, Inc.
Aprea Therapeutics is a clinical-stage oncology company that discovers and develops targeted therapies for patients with biomarker-defined cancers. It focuses on synthetic lethality, using small molecule inhibitors intended to exploit cancer-related genetic mutations. Its lead clinical-stage programs are APR-1051, a WEE1 inhibitor, and ATRN-119, an ATR inhibitor, both being studied in patients with advanced solid tumors. Aprea also has APR-1602, a preclinical macrocyclic DYRK1A/B inhibitor, and is not currently conducting clinical trials involving its former mutant p53 reactivator, APR-246. Aprea contracts with third parties to manufacture product candidates and clinical trial materials, and retains worldwide development and commercialization rights to its candidates. It is headquartered in Doylestown, Pennsylvania.
No SEC Form 4 filings for $APRE in the last 30 days.
See all $APRE insider activity →Aprea Therapeutics reported no revenue and a net loss of $4.8M for Q3 2026, compared to $1.8K revenue and a $3M loss a year earlier. Diluted EPS was $(0.09). The company reported clinical trial updates for APR-1051 and ATRN-119, and plans to expand APR-1051 enrollment and target lead identification for APR-1602 in Q2 2027.
Aprea Therapeutics, Inc. (APRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aprea Therapeutics Announces Third Quarter 2026 Financial Results Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026) in Barcelona on November 20, 2026 APR-1051 Phase 1 c
Aprea Therapeutics reported $37.8M in cash as of September 30, 2026, with a runway into Q1 2028. The Phase 1 trial for APR-1051 expanded to nine sites, with interim data expected November 20, 2026.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning APRE (Aprea Therapeutics, Inc.). Coverage has been balanced: 1 bullish, 1 neutral, and 1 bearish.
Recent APRE coverage spans financial news, earnings and corporate actions.
The company posted a widening loss and zero revenue, indicating continued cash burn and limited near‑term revenue.
Positive clinical progress and sufficient cash runway likely support near‑term upside.
Cash runway extension reduces short‑term liquidity risk but offers no immediate upside catalyst.
The filing adds fresh, tradable updates on APR-1051 clinical execution and runway, which can shift near-term risk perception for the stock.
Reverse split authorization can affect near-term liquidity/valuation optics and may signal prior share-price pressure, but the exact ratio and timing remain board-discretionary.
AlphAI scores every news story that mentions APRE with an AI model for sentiment and relevance, and aggregates insider trades from Aprea Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aprea Therapeutics reported no revenue and a net loss of $4.8M for Q3 2026, compared to $1.8K revenue and a $3M loss a year earlier. Diluted EPS was $(0.09). The company reported clinical trial updates for APR-1051 and ATRN-119, and plans to expand APR-1051 enrollment and target lead identification for APR-1602 in Q2 2027.
1 min readAprea Therapeutics, Inc. (APRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aprea Therapeutics Announces Third Quarter 2026 Financial Results Updated interim Phase 1 data for oral WEE1 inhibitor APR-1051 to be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026) in Barcelona on November 20, 2026 APR-1051 Phase 1 c
2 min readAprea Therapeutics reported $37.8M in cash as of September 30, 2026, with a runway into Q1 2028. The Phase 1 trial for APR-1051 expanded to nine sites, with interim data expected November 20, 2026.
2 min readAprea Therapeutics, Inc. (APRE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Aprea Therapeutics Announces Second Quarter 2026 Financial Results Enrollment in the ongoing Phase 1 dose escalation ACESOT-1051 trial of oral WEE1 inhibitor APR-1051 is accelerating as dose escalation advances Aprea plans to advance APR-1051 in uterine serous
7 min readAprea Therapeutics, Inc. (APRE) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001781983 0001781983 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 16, 2026
3 min readAprea Therapeutics has filed a notice for the resale of up to 5.5 million shares by its selling stockholders. This information comes from a recent SEC filing. The company's stock symbol is APRE.
2 min readAprea Therapeutics (NASDAQ: APRE) has registered 74,349,426 shares of Common Stock for resale by selling stockholders. This registration covers shares issuable upon the exercise of both pre-funded warrants (37,174,713 shares) and common warrants (37,174,713 shares) that were issued in a private placement on March 31, 2026. Aprea Therapeutics will not receive proceeds from the resales themselves but will receive cash if the outstanding warrants are exercised, with proceeds intended for clinical trials, working capital, and general corporate purposes.
2 min readAprea Therapeutics announced that its abstract detailing early results from the first-in-human Phase 1 ACESOT-1051 study of the WEE1 inhibitor APR-1051 for advanced solid tumors has been accepted for presentation at the ASCO 2026 Annual Meeting. The presentation will be a poster session on May 30, 2026, featuring initial safety and activity findings. This marks a significant clinical milestone, with investors closely watching for efficacy, safety, and biomarker data.
4 min readAprea Therapeutics has secured approximately $30 million in gross proceeds through an oversubscribed private placement, extending its cash runway into Q1 2028. The company also reported positive clinical data from its Phase 1 ACESOT-1051 trial for WEE1 inhibitor APR-1051, showing a confirmed partial response in PPP2R1A-mutated endometrial cancer and generally manageable safety. This financing and promising trial data reinforce Aprea's commitment to developing targeted therapies for biomarker-defined cancers.
3 min readAprea Therapeutics (APRE) has shown early clinical proof-of-concept for APR-1051 in endometrial cancer and strengthened its financial position by raising $8.7 million. The company has narrowed its operating losses year-over-year, and its cash runway is projected to extend into Q1 2027. Further clinical updates are anticipated in Q2 2026, positioning the company for key milestones.
4 min read
